Pinned
Sully.ai
94 posts
Sully.ai
@sullyai
Autonomous OS for healthcare
- You can vibe code a scribe over the weekend, but look what happens when you launch a scribe in an integrated full-suite environment for clinicians. The "AI scribe" standalone category is already dead. Writing down what happens in a visit is the easy part. Every tool does that
00:00 - Sully.ai reposted
Every healthcare AI startup does the same thing: Build one tool. Spend 2 years chasing integration. Fail to show ROI to clients. Raise another round. Repeat. We said no. At @sullyai, we're introducing the 1st GMAH (General Medical Agent Harness) to bring the first fully
00:00 - Every healthcare AI startup does the same thing: Build one tool. Spend 2 years chasing integration. Fail to show ROI to clients. Raise another round. Repeat. We said no. At @sullyai, we're introducing the 1st GMAH (General Medical Agent Harness) to bring the first fully00:00
- More clarity on the Delve situation: You may have seen recent reporting about Delve, a compliance automation platform that is under scrutiny for allegedly producing fraudulent SOC 2 audit reports without properly verifying customers' security controls. We want to be transparent
- Every healthcare AI co is building for clinicians. Nobody's building for patients. That's the $50B mistake.
- Sully.ai reposted
Replying to @Speechmatics and @sullyaiThat's the world's first Arabic-English bilingual medical model in production. 📊 Powered by @NVIDIAHealth. speechmatics.com/company/articl…
- Excited to partner deeply with @Speechmatics to launch the world's first Arabic-English speech-to-text model.@sullyai tested the major STT providers on real MENA clinical audio. 👀 Code-switching, dialect-heavy consultations, the conditions generic models fail on. 🏥 Patrick Nguyen, Head of Engineering MENA: ours was the only one that hit the performance thresholds needed for clinical
- Sully.ai repostedHealthcare AI cos are solving the wrong problem. Clinicians don't need better diagnoses. They need time back. Here's the $100B insight:
